On Jan. 11, 2021, TheNew York Times posted an article about the virtues of fecal immunochemical testing relative to colonoscopy. The story, “A Colonoscopy Alternative Comes Home” [https://www.nytimes.com/ 2021/ 01/ 11/ health/ colonoscopy-health-home-testing.html] depicted colonoscopy as a comparatively risky procedure with few advantages over less invasive methods of testing for colorectal cancer. It also offered the speculation that financial factors— namely, greater reimbursement for endoscopy—was behind the general preference of gastroenterologists for colonoscopy over stool tests.
Trending
- 43% Lower Mortality Seen in Colorectal Screening Participants (HCP Live)
- BioNTech halts mRNA colorectal cancer vaccine trial after safety review (Reuters)
- Microdroplets may reduce colorectal tumor growth at potentially lower cost (Medical Xpress)
- What it takes to build a gut-health service line (GI & Hepatology News)
- Weight Down, Steps Down: The GLP-1 Catch (Medscape)
- Pediatric Gastroenterology Faces AI Reality Check (Medscape)
- Ayble Health Joins Amazon’s Health Benefits Connector to expand Virtual GI Care Access to Millions of Americans (PR Newswire)
- Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening (Guardant Health)
